1Moller, DE & Kaufman, KD (2005) Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 56, 45–62.
2Ford, ES, Li, C & Sattar, N (2008) Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 31, 1898–1904.
3Mottillo, S, Filion, KB, Genest, J, et al. (2010) The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56, 1113–1132.
4Kimokoti, RW & Brown, LS (2011) Dietary management of the metabolic syndrome. Clin Pharmacol Ther 90, 184–187.
5Riccardi, G, Giacco, R & Rivellese, AA (2004) Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr 23, 447–456.
6Bray, GA, Paeratakul, S & Popkin, BM (2004) Dietary fat and obesity: a review of animal, clinical and epidemiological studies. Physiol Behav 83, 549–555.
7Ryder, JW, Portocarrero, CP, Song, XM, et al. (2001) Isomer-specific antidiabetic properties of conjugated linoleic acid. Improved glucose tolerance, skeletal muscle insulin action, and UCP-2 gene expression. Diabetes 50, 1149–1157.
8Noone, EJ, Roche, HM, Nugent, AP, et al. (2002) The effect of dietary supplementation using isomeric blends of conjugated linoleic acid on lipid metabolism in healthy human subjects. Br J Nutr 88, 243–251.
9Henriksen, EJ, Teachey, MK, Taylor, ZC, et al. (2003) Isomer-specific actions of conjugated linoleic acid on muscle glucose transport in the obese Zucker rat. Am J Physiol Endocrinol Metab 285, E98–E105.
10Nagao, K, Inoue, N, Wang, YM, et al. (2003) Conjugated linoleic acid enhances plasma adiponectin level and alleviates hyperinsulinemia and hypertension in Zucker diabetic fatty (fa/fa) rats. Biochem Biophys Res Commun 310, 562–566.
11Inoue, N, Nagao, K, Hirata, J, et al. (2004) Conjugated linoleic acid prevents the development of essential hypertension in spontaneously hypertensive rats. Biochem Biophys Res Commun 323, 679–684.
12Moloney, F, Yeow, TP, Mullen, A, et al. (2004) Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. Am J Clin Nutr 80, 887–895.
13Choi, JS, Jung, MH, Park, HS, et al. (2004) Effect of conjugated linoleic acid isomers on insulin resistance and mRNA levels of genes regulating energy metabolism in high-fat-fed rats. Nutrition 20, 1008–1017.
14Noto, A, Zahradka, P, Yurkova, N, et al. (2006) Conjugated linoleic acid reduces hepatic steatosis, improves liver function, and favorably modifies lipid metabolism in obese insulin-resistant rats. Lipids 41, 179–188.
15Noto, A, Zahradka, P, Yurkova, N, et al. (2007) Dietary conjugated linoleic acid decreases adipocyte size and favorably modifies adipokine status and insulin sensitivity in obese, insulin-resistant rats. Metabolism 56, 1601–1611.
16Noto, A, Zahradka, P, Ryz, NR, et al. (2007) Dietary conjugated linoleic acid preserves pancreatic function and reduces inflammatory markers in obese, insulin-resistant rats. Metabolism 56, 142–151.
17Moloney, F, Toomey, S, Noone, E, et al. (2007) Antidiabetic effects of cis-9, trans-11-conjugated linoleic acid may be mediated via anti-inflammatory effects in white adipose tissue. Diabetes 56, 574–582.
18Halade, GV, Rahman, MM & Fernandes, G (2010) Differential effects of conjugated linoleic acid isomers in insulin-resistant female C57Bl/6J mice. J Nutr Biochem 21, 332–337.
19Gilbert, W, Gadang, V, Proctor, A, et al. (2011) trans–trans Conjugated linoleic acid enriched soybean oil reduces fatty liver and lowers serum cholesterol in obese Zucker rats. Lipids 46, 961–968.
20Declercq, V, Taylor, CG, Wigle, J, et al. (2012) Conjugated linoleic acid improves blood pressure by increasing adiponectin and endothelial nitric oxide synthase activity. J Nutr Biochem 23, 487–493.
21Tsuboyama-Kasaoka, N, Takahashi, M, Tanemura, K, et al. (2000) Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice. Diabetes 49, 1534–1542.
22Chung, S, Brown, JM, Provo, JN, et al. (2005) Conjugated linoleic acid promotes human adipocyte insulin resistance through NFkappaB-dependent cytokine production. J Biol Chem 280, 38445–38456.
23Wendel, AA, Purushotham, A, Liu, LF, et al. (2008) Conjugated linoleic acid fails to worsen insulin resistance but induces hepatic steatosis in the presence of leptin in ob/ob mice. J Lipid Res 49, 98–106.
24de Roos, B, Rucklidge, G, Reid, M, et al. (2005) Divergent mechanisms of cis9, trans11-and trans10, cis12-conjugated linoleic acid affecting insulin resistance and inflammation in apolipoprotein E knockout mice: a proteomics approach. FASEB J 19, 1746–1748.
25Cruz-Hernandez, C, Kramer, JK, Kennelly, JJ, et al. (2007) Evaluating the conjugated linoleic acid and trans 18:1 isomers in milk fat of dairy cows fed increasing amounts of sunflower oil and a constant level of fish oil. J Dairy Sci 90, 3786–3801.
26Lock, AL & Bauman, DE (2004) Modifying milk fat composition of dairy cows to enhance fatty acids beneficial to human health. Lipids 39, 1197–1206.
27Corl, BA, Barbano, DM, Bauman, DE, et al. (2003) cis-9, trans-11 CLA derived endogenously from trans-11 18:1 reduces cancer risk in rats. J Nutr 133, 2893–2900.
28Turpeinen, AM, Mutanen, M, Aro, A, et al. (2002) Bioconversion of vaccenic acid to conjugated linoleic acid in humans. Am J Clin Nutr 76, 504–510.
29Sommerfeld, M (1983) Trans unsaturated fatty acids in natural products and processed foods. Prog Lipid Res 22, 221–233.
30Chisholm, A, Mann, J & Skeaff, M (1995) Trans fatty acids: a cause for concern? Int J Food Sci Nutr 46, 171–176.
31Woodside, JV & Kromhout, D (2005) Fatty acids and CHD. Proc Nutr Soc 64, 554–564.
32Ascherio, A, Hennekens, CH, Buring, JE, et al. (1994) Trans-fatty acids intake and risk of myocardial infarction. Circulation 89, 94–101.
33Tholstrup, T (2006) Dairy products and cardiovascular disease. Curr Opin Lipidol 17, 1–10.
34Sun, Q, Ma, J, Campos, H, et al. (2007) A prospective study of trans fatty acids in erythrocytes and risk of coronary heart disease. Circulation 115, 1858–1865.
35Bendsen, NT, Christensen, R, Bartels, EM, et al. (2011) Consumption of industrial and ruminant trans fatty acids and risk of coronary heart disease: a systematic review and meta-analysis of cohort studies. Eur J Clin Nutr 65, 773–783.
36Wang, Y, Jacome-Sosa, MM, Ruth, MR, et al. (2009) Trans-11 vaccenic acid reduces hepatic lipogenesis and chylomicron secretion in JCR:LA-cp rats. J Nutr 139, 2049–2054.
37Wang, Y, Lu, J, Ruth, MR, et al. (2008) Trans-11 vaccenic acid dietary supplementation induces hypolipidemic effects in JCR:LA-cp rats. J Nutr 138, 2117–2122.
38Jacome-Sosa, MM, Lu, J, Wang, Y, et al. (2010) Increased hypolipidemic benefits of cis-9, trans-11 conjugated linoleic acid in combination with trans-11 vaccenic acid in a rodent model of the metabolic syndrome, the JCR:LA-cp rat. Nutr Metab (Lond) 7, 60.
39Bassett, CM, Edel, AL, Patenaude, AF, et al. (2010) Dietary vaccenic acid has antiatherogenic effects in LDLr − / − mice. J Nutr 140, 18–24.
40Kurtz, TW, Morris, RC & Pershadsingh, HA (1989) The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 13, 896–901.
41Kasiske, BL, O'Donnell, MP & Keane, WF (1992) The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19, I110–I115.
42Duffy, PE, Quinn, SM, Roche, HM, et al. (2006) Synthesis of trans-vaccenic acid and cis-9-trans-11-conjugated linoleic acid. Tetrahedron 62, 4838–4843.
43Declercq, V, Taylor, CG & Zahradka, P (2012) Isomer-specific effects of conjugated linoleic acid on blood pressure, adipocyte size and function. Br J Nutr 107, 1413–1421.
44Brouns, F, Bjorck, I, Frayn, KN, et al. (2005) Glycaemic index methodology. Nutr Res Rev 18, 145–171.
45Sethi, JK & Vidal-Puig, AJ (2007) Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res 48, 1253–1262.
46Tchoukalova, YD, Votruba, SB, Tchkonia, T, et al. (2010) Regional differences in cellular mechanisms of adipose tissue gain with overfeeding. Proc Natl Acad Sci U S A 107, 18226–18231.
47Lonn, M, Mehlig, K, Bengtsson, C, et al. (2010) Adipocyte size predicts incidence of type 2 diabetes in women. FASEB J 24, 326–331.
48Stender, S, Astrup, A & Dyerberg, J (2008) Ruminant and industrially produced trans fatty acids: health aspects. Food Nutr Res 52 .
49Mendis, S, Cruz-Hernandez, C & Ratnayake, WM (2008) Fatty acid profile of Canadian dairy products with special attention to the trans-octadecenoic acid and conjugated linoleic acid isomers. J AOAC Int 91, 811–819.
50Tholstrup, T, Raff, M, Basu, S, et al. (2006) Effects of butter high in ruminant trans and monounsaturated fatty acids on lipoproteins, incorporation of fatty acids into lipid classes, plasma C-reactive protein, oxidative stress, hemostatic variables, and insulin in healthy young men. Am J Clin Nutr 83, 237–243.
51Tardy, AL, Lambert-Porcheron, S, Malpuech-Brugere, C, et al. (2009) Dairy and industrial sources of trans fat do not impair peripheral insulin sensitivity in overweight women. Am J Clin Nutr 90, 88–94.
52Fruhbeck, G (2008) Overview of adipose tissue and its role in obesity and metabolic disorders. Methods Mol Biol 456, 1–22.
53Azain, MJ, Hausman, DB, Sisk, MB, et al. (2000) Dietary conjugated linoleic acid reduces rat adipose tissue cell size rather than cell number. J Nutr 130, 1548–1554.
54DeClercq, V, Zahradka, P & Taylor, CG (2010) Dietary t10, c12-CLA but not c9, t11 CLA reduces adipocyte size in the absence of changes in the adipose renin–angiotensin system in fa/fa Zucker rats. Lipids 45, 1025–1033.
55Skurk, T, Alberti-Huber, C, Herder, C, et al. (2007) Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92, 1023–1033.
56Kershaw, EE & Flier, JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89, 2548–2556.
57Couper, KN, Blount, DG & Riley, EM (2008) IL-10: the master regulator of immunity to infection. J Immunol 180, 5771–5777.
58Bogaert, YE & Linas, S (2009) The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol 5, 101–111.
59Yvan-Charvet, L, Massiera, F, Lamande, N, et al. (2009) Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology 150, 1421–1428.
60Duke, LM, Evans, RG & Widdop, RE (2005) AT2 receptors contribute to acute blood pressure-lowering and vasodilator effects of AT1 receptor antagonism in conscious normotensive but not hypertensive rats. Am J Physiol Heart Circ Physiol 288, H2289–H2297.
61Srinivasan, K & Ramarao, P (2007) Animal models in type 2 diabetes research: an overview. Indian J Med Res 125, 451–472.